There's a fresh glimmer of hope for Alzheimer's patients thanks to a new commitment from Johnson & Johnson to develop research from Melbourne's St Vincent's Institute of Medical Research (SVI), while most pharmaceutical giants are backing away from the complex disease.
The commitment marks the first time the global healthcare giant has extended a collaboration with an Australian research institution into an effort to develop and commercialise a product within Johnson & Johnson or one of its subsidiaries.
Loading...
Yolanda Redrup is the editor of the AFR Rich List. She previously reported on technology, healthcare and Street Talk. Connect with Yolanda on Twitter. Email Yolanda at yolanda.redrup@afr.com
